Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ramasamy Bhanumathi"'
Publikováno v:
ACS Omega, Vol 3, Iss 7, Pp 8317-8328 (2018)
Externí odkaz:
https://doaj.org/article/256034574a444922bc5d6a3f4ca57a2c
Autor:
Soundarapandian Kannan, Ramasamy Bhanumathi, Krishnamurthy Shanthi, Ramasundaram Thangaraj, Karuppaiya Vimala
Publikováno v:
New Journal of Chemistry. 41:14466-14477
Development of a nano-drug cum nano-carrier in a single platform seems to be conquered by almost a missionary fanaticism towards unraveling more and more about the bioavailability and anticancer activity at the molecular level. The present work mainl
Publikováno v:
ACS Omega
ACS Omega, Vol 3, Iss 7, Pp 8317-8328 (2018)
ACS Omega, Vol 3, Iss 7, Pp 8317-8328 (2018)
Currently, in clinics, breast cancer is treated with free chemotherapeutic drugs, as a result there is not much therapeutic effect in treated models, leading to substantial systemic toxicity. To overcome these critical problems for the primary outcom
Autor:
Ramasamy Bhanumathi, Ramar Thangam, Srinivasan Sivasubramanian, Ramasamy Thirumurugan, Kathirvel Rayappan, Raju Vivek, Soundarapandian Kannan, Atanu Bhattacharyya, Palani Gunasekaran, Chandran Murugan, Krishnamurthy Shanthi
Publikováno v:
Scientific Reports. 6
Scientific Reports 6: Article number: 34053; published online: 11 October 2016; updated: 29 November 2016
Autor:
Ramasamy Thirumurugan, Srinivasan Sivasubramanian, Palani Gunasekaran, Soundarapandian Kannan, Kathirvel Rayappan, Chandran Murugan, Ramar Thangam, Raju Vivek, Atanu Bhattacharyya, Ramasamy Bhanumathi, Krishnamurthy Shanthi
Publikováno v:
Scientific Reports
Combination therapy of multiple drugs through a single system is exhibiting high therapeutic effects. We investigate nanocarrier mediated inhibitory effects of topotecan (TPT) and quercetin (QT) on triple negative breast cancer (TNBC) (MDA-MB-231) an